echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > State Drug Administration notice: a batch of drugs suspended sales, recall.

    State Drug Administration notice: a batch of drugs suspended sales, recall.

    • Last Update: 2020-07-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The circular shows that after the Henan Province Food and Drug Inspection Institute and other 9 drug inspection institutions, marked as Jiangsu Wu Chinese Medicine Group Co., Ltd. Suzhou Pharmaceutical Factory and other 14 pharmaceutical manufacturers produced 25 batches of drugs do not meet the requirements.
    notice that, for the above non-compliant drugs, the drug regulatory department has asked the relevant enterprises and units to take risk control measures such as suspension of sales and use, recall, etc., to investigate the reasons for non-compliance and to carry out effective rectification.
    at the same time, the State Drug Administration requires the relevant provincial drug supervision and administration departments, in accordance with the Drug Administration Law of the People's Republic of China, to organize investigations into the illegal acts of the above-mentioned enterprises and units in the production and sale of counterfeit and inferior drugs, and to publicly investigate and investigate the results in accordance with the provisions.
    as follows: By the Henan Province Food and Drug Inspection Institute inspection, marked as Jiangsu Wu Chinese Medicine Group Co., Ltd. Suzhou Pharmaceutical Factory produced 9 batches of injection with amika star sulfate does not meet the regulations, does not meet the provisions of the project for the clarity and color of the solution.
    by the Guangxi Zhuang Autonomous Region Food and Drug Inspection Institute, marked as Anhui Guozheng Pharmaceutical Co., Ltd. produced a batch of compound-based xylitol potassium sulfonate oral solution does not meet the provisions, does not meet the provisions of the item for loading.
    by the Jiangsu Province Food and Drug Supervision and Inspection Research Institute inspection, marked as Hunan Warner Big Pharmaceutical Co., Ltd. produced a batch of Lansora intestinal soluble tablets do not comply with the regulations, non-compliance with the provisions of the project is dissolved.
    by the Shanghai Food and Drug Inspection Institute, marked as Hainan General Kangli Pharmaceutical Co., Ltd. produced 4 batches of injection of ozagray sodium does not comply with the regulations, non-compliance with the provisions of the item is visible foreign matter.
    by the Hubei Province Drug Supervision and Inspection Research Institute inspection, marked as Changchun People's Pharmaceutical Group Co., Ltd. produced 1 batch of infant spleen dispersion does not meet the provisions, does not meet the provisions of the item for the granularity.
    by the Sichuan Food and Drug Inspection and Inspection Institute, marked as Jiangxi Hongshuo Pharmaceutical Co., Ltd. produced 1 batch of Yuanhu painkillers do not comply with the provisions, non-compliance with the provisions of the item for content determination;
    by the China Food and Drug Inspection Research Institute inspection, marked as Hebei Jixin Tang Pharmaceutical Co., Ltd. produced 1 batch of broad fennel incense does not comply with the provisions, does not meet the provisions of the item is a characteristic.
    by Anhui Province Food and Drug Inspection Research Institute inspection, marked as Chongqing Sanlitang Chinese Medicine Pharmaceutical Co., Ltd., Chengdu Ji'ankang Pharmaceutical Co., Ltd., Neijiang Lianghui Pharmaceutical Co., Ltd. produced 3 batches of yellow essence does not meet the provisions, does not meet the provisions of the project as a characteristic.
    by the Dalian Drug Inspection and Inspection Institute inspection, marked as Xinjiang Herb Hall Pharmaceutical Co., Ltd. produced a batch of pre-Hu non-compliance with the regulations, non-compliance with the provisions of the item as a characteristic.
    by the China Food and Drug Inspection Research Institute inspection, marked as Chengdu Yulong Chinese medicine tablets Co. , Ltd. produced a batch of Sichuan Wu does not comply with the regulations, non-compliance with the provisions of the item is a characteristic.
    attached: small knowledge of non-compliant items One, the clarity of the solution is to compare the drug solution with the prescribed turbidity standard liquid, to check the degree of clarification of the solution; the clarity and color of the
    solution can reflect the purity of the drug to some extent, and it is a method that can carry out the drug quality check quickly, easily and accurately.
    2. The loading system reflects the weight or capacity of the drug, is applicable to solid, semi-solid, liquid preparations, the provisions should be in accordance with the minimum load inspection method for inspection, non-compliance will lead to insufficient clinical dose.
    3, solubility refers to the rate and degree of the dissolution of the active drug from the formulation, non-compliance will affect the absorption of the drug, reduce the degree of biological utilization.
    . Visible foreign body refers to the insoluble substance that is present in injection sinnuse, eye liquid preparation, which can be observed under the specified visual conditions, and its particle size or length is usually greater than 50 microns.
    V. The particle size is the size of the particles, the drug has the particle size requirements of the formulation products such as granules, dispersants, mixed suspension eye drops, mixed suspension ointments, etc. will carry out the project's setting, non-compliance may lead to the main component of the drug content of one uneven.
    , content determination refers to the use of the prescribed test methods to determine the content of the active ingredients in raw materials and preparations, generally by using chemical, instrument or biometric methods.
    seven, gold amine O is a pigment or dye, the detection of the ingredient, indicating that there is dyeing phenomenon.
    eight, the characteristics of the drug are recorded under the characteristics, odor, taste, solubility and physical constants, to a certain extent, reflect the quality characteristics of the drug.
    chinese medicine drink tablets does not comply with the provisions, may involve the deviation of the genus of the medicinal material, the preparation process is defective, improper storage and other circumstances.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.